article thumbnail

WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threats

Fierce Pharma

New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. | federal funding has sent shares tumbling in recent days.

Biopharma 307
article thumbnail

In biopharma, employees at Novartis, GSK, AZ and Genentech are most satisfied with their compensation: analysis

Fierce Pharma

A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields. 2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. |

Biopharma 227
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Capturing COVID: Biopharma through the lens during the pandemic

Fierce Pharma

A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. After wreaking havoc on a pandemic level for more than three years, COVID-19 has entered its first endemic season. | Now, we’re showcasing those precious memories here.

Biopharma 178
article thumbnail

Embracing Personalization in Biopharma Patient Support Programs

Fierce Pharma

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 246
article thumbnail

Biopharma staffers exhausted and susceptible to burnout, report says

Fierce Pharma

Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52

Biopharma 304
article thumbnail

Biopharma dealmaking: predictions for 2024

European Pharmaceutical Review

The past 12 months has seen significant growth in global mergers and acquisitions (M&A) within the biopharma sector. This activity is expected to continue in 2024, with increasing need for biopharma to access innovation through collaboration and dealmaking to offset looming patent challenges. “In

Biopharma 102
article thumbnail

Johnson & Johnson acquires Ambrx Biopharma for $2bn

Pharmaceutical Technology

Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a transaction valued at approximately $2bn.

Biopharma 111